Front. Bioeng. Biotechnol.
Frontiers in Bioengineering and Biotechnology
Front. Bioeng. Biotechnol.
2296-4185
Frontiers Media S.A.
1229416
10.3389/fbioe.2023.1229416
Bioengineering and Biotechnology
Correction
Corrigendum: Kinetic studies and CFD-based reaction modeling for insights into the scalability of ADC conjugation reactions
Weggen et al.
10.3389/fbioe.2023.1229416
Weggen
Jan Tobias
1
Seidel
Janik
1
Bean
Ryan
2
Wendeler
Michaela
2
Hubbuch
Jürgen
1
*
1
Institute of Process Engineering in Life Sciences, Section IV: Biomolecular Separation Engineering, Karlsruhe Institute of Technology (KIT), Karlsruhe, Germany
2
Purification Process Sciences, BioPharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, MD, United States
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
*Correspondence: Jürgen Hubbuch, juergen.hubbuch@kit.edu
09
06
2023
2023
11
1229416
26
05
2023
31
05
2023
Copyright © 2023 Weggen, Seidel, Bean, Wendeler and Hubbuch.
2023
Weggen, Seidel, Bean, Wendeler and Hubbuch
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A Corrigendum on Kinetic studies and CFD-based reaction modeling for insights into the scalability of ADC conjugation reactions by Weggen JT, Seidel J, Bean R, Wendeler M and Hubbuch J (2023). Front. Bioeng. Biotechnol. 11:1123842. doi: 10.3389/fbioe.2023.1123842
antibody-drug conjugate (ADC)
conjugation reaction
computational fluid dynamics (CFD)
mixing
scale-up
single-use
kinetic modeling
section-at-acceptance
Bioprocess Engineering
In the published article, there was an error in Affiliation [2]. Instead of “Purification Process Sciences, BioPharmaceuticals Development, Gaithersburg, MD, United States” it should be “Purification Process Sciences, BioPharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, MD, United States”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Conflict of interest
Authors MW and RB are employed by AstraZeneca PLC.
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.